HK1036016A1 - Inhibitors of complement activation - Google Patents

Inhibitors of complement activation

Info

Publication number
HK1036016A1
HK1036016A1 HK01106981A HK01106981A HK1036016A1 HK 1036016 A1 HK1036016 A1 HK 1036016A1 HK 01106981 A HK01106981 A HK 01106981A HK 01106981 A HK01106981 A HK 01106981A HK 1036016 A1 HK1036016 A1 HK 1036016A1
Authority
HK
Hong Kong
Prior art keywords
factor
inhibitors
complement activation
antibody
complement
Prior art date
Application number
HK01106981A
Other languages
English (en)
Inventor
Michael S C Fung
Cecily R Y Sun
Bill N C Sun
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1036016A1 publication Critical patent/HK1036016A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK01106981A 1998-02-20 2001-10-04 Inhibitors of complement activation HK1036016A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7532898P 1998-02-20 1998-02-20
PCT/US1999/003566 WO1999042133A1 (en) 1998-02-20 1999-02-19 Inhibitors of complement activation

Publications (1)

Publication Number Publication Date
HK1036016A1 true HK1036016A1 (en) 2001-12-21

Family

ID=22124992

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01106981A HK1036016A1 (en) 1998-02-20 2001-10-04 Inhibitors of complement activation

Country Status (18)

Country Link
US (1) US7439331B2 (zh)
EP (6) EP3056516A1 (zh)
JP (1) JP4437192B2 (zh)
KR (1) KR100425965B1 (zh)
CN (2) CN100366293C (zh)
AT (1) ATE412431T1 (zh)
AU (1) AU762050B2 (zh)
BR (2) BRPI9909220B1 (zh)
CA (1) CA2321140C (zh)
CY (1) CY1108663T1 (zh)
DE (1) DE69939813D1 (zh)
DK (2) DK2033659T3 (zh)
ES (3) ES2446930T3 (zh)
HK (1) HK1036016A1 (zh)
NZ (1) NZ506920A (zh)
PT (1) PT1054693E (zh)
SI (2) SI1054693T1 (zh)
WO (1) WO1999042133A1 (zh)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
EP2500438A3 (en) * 2002-09-25 2012-11-28 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
EP1572116A4 (en) * 2002-11-26 2007-12-12 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
CN103505728A (zh) 2005-05-26 2014-01-15 科罗拉多大学评议会法人机构 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
CN107929731A (zh) 2005-11-04 2018-04-20 健泰科生物技术公司 利用补体途径抑制剂治疗眼部疾病
WO2007141004A1 (en) * 2006-06-09 2007-12-13 Bayer Healthcare Ag Use of adipsin (adn) as a therapeutic or diagnostic target
ES2523640T3 (es) 2006-06-21 2014-11-28 Musc Foundation For Research Development Direccionamiento del factor H del complemento para el tratamiento de enfermedades
ES2700609T3 (es) 2006-11-02 2019-02-18 Genentech Inc Anticuerpos anti-factor D humanizados y sus usos
PL1920781T3 (pl) * 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
HUE026001T2 (en) * 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
EP2118142A2 (en) 2007-03-14 2009-11-18 Taligen Therapeutics, Inc. Humaneered anti-factor b antibody
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
RU2473563C2 (ru) * 2007-06-07 2013-01-27 Дженентек, Инк. АНТИТЕЛА ПРОТИВ C3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ
CR20170001A (es) * 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
ME01699B (me) 2009-07-02 2014-09-20 Musc Found For Res Dev Metode za stimulaciju regeneracije jetre
MX2012005151A (es) 2009-11-05 2012-08-23 Federico Ii University Of Naples Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular.
MX2012013233A (es) 2010-05-14 2013-05-20 Univ Colorado Regents Grupos que apuntan a receptor 2 de complemento (cr2) mejorados.
KR20130036276A (ko) 2010-06-22 2013-04-11 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 보체 결합 3의 C3d 조각에 대한 항체들
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
CN110818798A (zh) * 2012-10-25 2020-02-21 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
ES2514165B1 (es) * 2013-03-27 2015-09-09 Consejo Superior De Investigaciones Científicas (Csic) Anticuerpo anti-factor b, composición farmacéutica útil para el tratamiento de enfermedades del complemento y sus aplicaciones
EA034870B1 (ru) 2013-08-07 2020-03-31 Алексион Фармасьютикалз, Инк. Белковые биомаркеры атипичного гемолитического уремического синдрома
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
WO2015168468A1 (en) 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
US10534004B2 (en) * 2014-05-02 2020-01-14 Uab Research Foundation Methods and compositions for diagnosis and treatment of meningitis
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MA43072A (fr) * 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
JP2018531980A (ja) * 2015-10-30 2018-11-01 ジェネンテック, インコーポレイテッド 抗d因子抗体製剤
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック, インコーポレイテッド 抗d因子抗体及びコンジュゲート
JP6911026B2 (ja) 2015-10-30 2021-07-28 ジェネンテック, インコーポレイテッド D因子活性及びd因子阻害剤の力価を測定する方法
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
US11007254B2 (en) 2016-10-17 2021-05-18 Musc Foundation For Research Development Compositions and methods for treating central nervous system injury
BR112019016574A2 (pt) * 2017-02-10 2020-03-31 The Trustees Of The University Of Pennsylvania Anticorpo, método para tratar uma doença ou distúrbio mediado por via alternativa em um indivíduo e para reduzir a atividade de uma via alternativa de um sistema complemento de um indivíduo, animal não humano geneticamente modificado, e, célula.
WO2018191548A2 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
JP2022553640A (ja) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド 眼障害を処置する方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5861156A (en) * 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
US5856300A (en) 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
WO1995025540A1 (en) 1994-03-23 1995-09-28 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) * 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US7112327B2 (en) * 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation

Also Published As

Publication number Publication date
AU2870099A (en) 1999-09-06
DE69939813D1 (de) 2008-12-11
CN1298308A (zh) 2001-06-06
KR20010040585A (ko) 2001-05-15
SI2033659T1 (sl) 2014-03-31
US7439331B2 (en) 2008-10-21
CN101298481A (zh) 2008-11-05
ES2446930T3 (es) 2014-03-10
EP2033659B1 (en) 2013-12-04
AU762050B2 (en) 2003-06-19
JP2002503706A (ja) 2002-02-05
EP2033659A3 (en) 2009-08-19
KR100425965B1 (ko) 2004-04-06
DK2033659T3 (en) 2014-02-17
EP1054693B8 (en) 2009-03-04
ATE412431T1 (de) 2008-11-15
CA2321140A1 (en) 1999-08-26
CN100366293C (zh) 2008-02-06
EP1054693B1 (en) 2008-10-29
US20060240020A1 (en) 2006-10-26
EP2848634A1 (en) 2015-03-18
EP2033659A2 (en) 2009-03-11
WO1999042133A1 (en) 1999-08-26
EP3260467A1 (en) 2017-12-27
DK1054693T3 (da) 2008-12-08
BR9909220A (pt) 2000-11-21
EP2277920A2 (en) 2011-01-26
EP1054693A1 (en) 2000-11-29
JP4437192B2 (ja) 2010-03-24
CA2321140C (en) 2015-04-07
ES2317689T3 (es) 2009-04-16
PT1054693E (pt) 2009-01-22
EP2277920B1 (en) 2014-06-11
NZ506920A (en) 2003-12-19
ES2488819T3 (es) 2014-08-29
EP2277920A3 (en) 2012-11-14
EP1054693A4 (en) 2005-03-23
SI1054693T1 (sl) 2009-04-30
BRPI9909220B1 (pt) 2018-09-18
CY1108663T1 (el) 2014-04-09
EP3056516A1 (en) 2016-08-17

Similar Documents

Publication Publication Date Title
EP1054693B8 (en) Inhibitors of complement activation
PT1265929E (pt) Inibidores anti-c2/c2a de activação complementar
HK1225741A1 (zh) 用於治療和預防異種移植或急性血管排斥反應的補體c5激活的抑制
NO2017040I2 (no) Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC
KR960704576A (ko) CD40에 대한 항체(Antibodies to CD40)
RS80704A (en) ANTI- av?6.ANTIBODIES
SG156547A1 (en) Human monoclonal antibodies to ctla-4
TW200722518A (en) Sc(fv)2 structural isomers
NZ611387A (en) Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
ATE335072T1 (de) Methoden für inhibition der cd14-abhängigen zellaktivierung
HRP20090527T1 (en) Nogo-a neutralising immunoglobulins for treatment of neurological diseases
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
IL162117A0 (en) Humanized collagen antibodies and methods utilizing the same
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
IL139571A0 (en) A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same
EP1468022A4 (en) NEW MONOCLONAL ANTIBODY AND LARVAL NEMATODIAN ANTIGENS
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk
SE9501302D0 (sv) Antibodies for use in cancertherapy and diagnosis

Legal Events

Date Code Title Description
PE Patent expired